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We thank our colleagues Cheng and
associates for their commentary with
regard to our recently published article,
‘‘The Sentinel Node Concept in Ade-
nocarcinomas of the Distal Esophagus
and Gastroesophageal Junction.’’1 In
this study, we used the widely recog-
nized immunohistochemical assay in
which antibodies against epithelial-
cell proteins are used to detect small
clusters of tumor cells in histologically
node-negative lymph nodes of patients
with esophageal adenocarcinoma. Yao
and Han claim that the monoclonal an-
tibody against cytokeratin 8 and 18
(clone NCL-5D3) that we used in the
present study should not be mistaken
with the CAM5.2 antibody (clone
CAM5.2) that appears to be specific
for cytokeratin 7 and 8. In our article,
we stated that the used antibody
CAM 5.2 is specific for intracellular
cytokeratin 8 and 18, referring to the
original paper of Makin, Bobrow, and
Bodmer,2 in which it is claimed that
(at that time newly developed)
antibody CAM5.2 identifies the lower
molecular weight cytokeratins (cyto-
keratin 8, 18 and 19). Other studies
that investigated the presence and
relevance of micrometastases or iso-
lated tumor cells by using antibody
CAM5.2 have also referred to this arti-
cle.3 However, over the last years,
companies producing these antibodiesThe Journalhave changed their products and fur-
ther investigated the corresponding
specificity in reactivity against certain
cytokeratins, as pointed out by Yao
and Han. Therefore, their statement
that antibody CAM5.2 is not specific
for intracellular cytokeratin 8 and 18
is correct. Nevertheless, this finding
does not affect the conclusions of our
study. The presence of cytokeratin 8
and/or 18 (which are both expressed
in esophageal adenocarcinoma4) as
detected with the antibody used in
our study (clone NCL-5D3) indicates
epithelial cell deposits in lymphoid
tissue. Therefore, these cytokeratin
deposits will still imply the presence
of micrometastatic disease.
Brechtje A. Grotenhuis
Bas P. L. Wijnhoven
Herman van Dekken
J. Jan B. van Lanschot
Erasmus Medical Center
Rotterdam, The Netherlands
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To the Editor:
We read with great interest the arti-
cle by Atluri and colleagues,1 and weof Thoracic and Cardiovascular Surgercongratulate them for their experi-
ments with myocardial perfusion and
contractility improvement using a laser
transmyocardial approach. We agree
with the authors that the problem
with myocardial revascularization in
patients who might not benefit from
conventional procedures still demands
investigative efforts. This was the gen-
esis of a research program we began at
Laval University in Quebec and that
we are going to start in Europe at Uni-
versite´ Paris Sud. This program is
aimed at the enhancement of noncoro-
nary collateral circulation (NCCC).
Our animal models are dogs (Canada)
and pigs (France).
NCCC is a topic that is virtually ig-
nored,with very fewpublications in ex-
istence. This is surprising, considering
that it is not rare to find evidence of
NCCC, such as during coronary bypass
surgerywhen arterial blood flowcomes
from the coronary ostia during valve re-
placement surgery or from the incised
coronary artery, despite adequate aortic
crossclamping and venting. NCCC
consists of a network of small channels
that come from mediastinal, bronchial,
and pericardial vessels and that enter
the heart through the pericardial reflec-
tions surrounding the pulmonary and
systemic veins, as well as through the
vasa vasorum of the aorta and pulmo-
nary artery leading to and from the
myocardium. Our studies are premised
on the belief that this network is bigger
than generally thought and that it might
play a role, if adequately enhanced, as
an alternative means of myocardial
blood supply. We also believe that the
normal ventricular function sometimes
seen in patients with occlusion of the 3
major coronary vessels can be evidence
of myocardial nourishment related to
such a collateral source. Previous stud-
ies2 have shown that vascular connec-
tions exist between the internal
thoracic arteries (ITAs) and myocar-
dium and that surgical bilateral ligation
of the ITAs creates a local hypertensive
status, increasing the perfusion pres-
sure within the channels leading to the
heart.3y c Volume 139, Number 6 1675
Letters to the EditorBefore cardiopulmonary bypass be-
came widespread, some groups in
Italy2 and the United States3 per-
formed ligation of the ITAs in canine
models and human subjects with is-
chemic heart disease. Reported results
were promising: angina disappeared,
correlating with the disappearance
of ischemic signs at electrocardiogra-
phy. We believe that these data should
be re-explored with the help of
modern technology. Our hypothesis4,5
has been that administration of angio-
genic growth factors combined with
distal occlusion of the ITAs might en-
hance angiogenesis of NCCC.We per-
formed surgical ligature of the ITAs
distally, and vascular endothelial
growth factor was administered into
the occluded arteries. Intuitively, oc-
clusion by means of endovascular em-
bolization is possible as well. It is
known that the ITAs have high plastic
potential, being capable of developing
major branches that work as the only
source of blood in extreme cases of
lower limb ischemia.6 Hence myocar-
dial ischemia should also be able to
stimulate noncoronary collateral blood
flow, preferably diverting this to the
diseased area rather than to the chest
wall.
It will be neither easy nor quick to
demonstrate such theories, but our cur-
rent studies represent a parallel, alter-
native research field, moving in the
same direction of laser transmyocar-
dial revascularization.
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With great interest, we read Piciche`
and associates’ letter entitled, ‘‘Angio-
genesis and surgical or endovascular
enhancement of noncoronary collat-
eral circulation: a new research field.’’
We thank the authors for their kind
comments regarding our article on the
neovasculogenic effects of transmyo-
cardial revascularization. We agree
wholeheartedly with the authors that
in patients with coronary artery dis-
ease, noncoronary collateral circula-
tion and the microvasculature
comprise critical components of myo-
cardial perfusion and viability and
hence greatly affect cardiomyocyte
and ventricular function.Although sur-
gical and percutaneous coronary ther-
apy and investigative research are
focused predominantly on large epicar-
dial coronary vessels, the small collat-Cardiovascular Surgery c June 2010erals and microvasculature are greatly
underappreciated and understudied.
Certainly there are abundant clinical
anecdotes of patients surviving on vari-
ous permutations of coronary and
noncoronary collaterals. Clinicians
have all encountered the patient with
an angiographically absent major coro-
nary artery yetwith the subtendedmyo-
cardium demonstrating completely
normal contractility on echocardio-
graphic analysis. Is such a large region
supplied through coronary collaterals,
noncoronary collaterals from the base
of the heart and posterior pericardial re-
flection or perhaps through the highly
vascularized adhesions that surgeons
encounter when operating on patients
with prior cardiac surgery, renal failure,
or myocardial infarction and Dressler
syndrome? In older patients and in
states of chronic disease, the ability to
generate such collaterals can be im-
paired.1,2 Researchers are beginning to
understand the critical interrelated roles
of endogenous myocardium-mediated
proangiogenic signaling and bone mar-
row–derived endothelial progenitor
cells.3,4 Although initially very promis-
ing, the results of clinical trials aimed at
harnessing this intrinsic revasculariza-
tion machinery have been clinically
equivocal.5-7 Perhaps what is needed
is a refocus on augmenting noncoro-
nary collaterals as an additional driving
force in therapeutic neovascularization.
The authors present a very intrigu-
ing strategy of ligating both distal in-
ternal thoracic arteries to produce
a regional state of hypertension and
hyperperfusion around the mediasti-
num. Coupled with local delivery of
angiogenic cytokines, the authors
propose to enhance the development
of noncoronary collaterals to reper-
fuse the ischemic myocardium in 2
large animal models. The preliminary
background data presented by the au-
thors is encouraging. Although
critics will focus on the preclusion
of a future left internal thoracic ar-
tery–left anterior descending coro-
nary artery graft, the cornerstone of
coronary artery bypass grafting
